Renan Ozyerli, MD, MSD Turkey
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD entered the Turkish pharma market in 1989 and established a subsidiary in 1993.
The headquarters are based in Istanbul. MSD employs 463 people in Human Health, as well as 32 people in Animal Health. Products are sourced from the global MSD network and toll manufacturing from 4 local companies. The subsidiary has a fully operational warehouse.
Currently, MSD Turkey is participating in 23 international clinical trials at 113 study centers. As such, the affiliate ranks among the top 3 research-based pharma companies in terms of clinical research capability. MSD Turkey also houses the management oversight/responsibility of Middle East and Egypt with 6 trials and 21 study centers in 5 different countries. In 2014, Merck HQ funded TRY 20.7 million (USD 9.5 million) to Turkey for clinical trials.
Contact Details
Merck Sharp Dohme İlaçları Ltd. Şti.
Esentepe Mah. Büyükdere Cad. No: 199
Levent 199 Ofis Bloğu Kat: 13, 34394 Levent-İstanbul
Tel:+90 212 336 1000
Fax:+90 212 215 2733
http://www.msd.com.tr/
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
In an environment where the line between generic and innovator companies is less and less relevant, due to the growing trend of innovators integrating generics products in their portfolio through…
Poland and Turkey present many similarities, in terms of market size and frequency of reforms for instance, but also a lot of differences, as the generic penetration is much lower…
Currently, what are the main priorities and goals of ISPAT related to the Healthcare and Pharmaceuticals sector, and what are the overall strategies designed to achieve these objectives? As an…
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Can you describe the current investment climate in Turkey for pharma companies? Turkey’s economic and political situation are very important factors to consider for foreign investors. Over the last three…
Mr. Ediz Günsel, could you introduce yourself to our readers ? Yes; I have been with the firm over twenty years, including 5 years with PwC London. In my twenty…
At Reckitt Benckiser, you have gradually taken positions of increasing responsibility over the last decade in Marketing. What would you highlight as the main specificities of Turkish market compared to…
The company entered the Turkish market in 2005, and made important product launches in 2008. You have been General Manager of Ferring Turkey over those last 7 years. Can you…
Would you like to come back for our readers on the main milestones in Daiichi Sankyo’s development over the past few years in Turkey and how it positions itself in…
You have pharmaceuticals production in your background and have recently joined PharmaVision as General Manager. To what extent does this speak about the company’s direction? Could you elaborate on your…
Mr Fadıllıoğlu, after a previous position at Abbott, you were recently appointed head of GSK Turkey. How different is GSK as an organization? What new therapeutic areas, processes, or corporate…
Mr Acar, could you present to our readers the Institution’s historical development and its role today in the Turkish pharmaceutical and healthcare sector? Before Social Security Reform was initiated, there…
See our Cookie Privacy Policy Here
